S
Stargazer Pharmaceuticals
An ophthalmic biotech company focused on the development of a novel treatment option for a genetic orphan retinal disease with significant unmet medical needs
About Stargazer Pharmaceuticals
Stargazer Pharmaceuticals Inc is a biotech company specializing in ophthalmic treatments, particularly for Stargardt Disease, a rare genetic retinal disorder with significant unmet medical needs. The company operates in the biotechnology and pharmaceutical market, focusing on developing novel therapeutic solutions for eye diseases. Stargazer's core product, STG-001, is an indirect visual cycle modulator that reduces plasma concentrations of Retinol Binding Protein 4 (RBP4), thereby slowing down the visual cycle and accumulation of toxic retinoids in the eye. This innovative approach aims to provide a much-needed treatment option for patients suffering from Stargardt Disease.
Stargazer Pharmaceuticals primarily serves patients with rare ophthalmic conditions, working closely with healthcare providers and medical institutions. The company's business model revolves around research and development, clinical trials, and eventual commercialization of their proprietary treatments. Revenue is generated through the sale of their therapeutic products, partnerships, and potential licensing agreements.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Nov 2020 | $57M | $228M | Canaan · Novo Holdings · Pontifax Funds · Retinal Degeneration Fund | — |
| EARLY VCOther financing | Apr 2018 | $28M | $114M | Undisclosed | — |
Growth signals
Latest recorded traffic for Stargazer Pharmaceuticals is 140 monthly website visits, down 44% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Stargazer Pharmaceuticals in the Boston ecosystem
The Stargazer Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Canaan
Novo Holdings
Pontifax Funds
Retinal Degeneration Fund
venBio Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Stargazer Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Stargazer Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










